<p><strong>SAN FRANCISCO</strong> &#8212; Venture capital firm venBio has closed venBio Global Strategic Fund V (“venBio Fund V”), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds.</p>
<p>Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goodman, Ph.D., and Aaron Royston, M.D., venBio Fund V will maintain its focus on life science companies that are developing biopharmaceuticals to address unmet medical needs. The venBio team takes an active role with each portfolio company, providing strategic guidance on a range of research, clinical, and business activities. venBio seeks opportunities spanning all stages of clinical development, with a focus on those providing meaningful clinical data and value inflection within three to five years.</p>
<p>“With a highly concentrated portfolio and active involvement in each company, we are proud to have helped build companies that have achieved nine FDA drug approvals over the past six years, with many more generating promising clinical efficacy and safety data,” said Dr. Royston. “This cohort of companies has generated significant value for venBio, and it’s motivating to recognize that by turning science into impactful medicine, our firm and our partners have been rewarded.”</p>
<p>Since inception in 2011, venBio has raised roughly $2B billion in capital commitments and led investment rounds in 40+ companies, including Labrys Biologics (acquired by Teva), Aragon Pharmaceuticals (acquired by Johnson &#038; Johnson), Seragon Pharmaceuticals (acquired by Roche), Aurinia Pharmaceuticals (NASDAQ: AUPH), Apellis Pharmaceuticals (NASDAQ: APLS), Checkmate Pharmaceuticals (NASDAQ: CMPI, acquired by Regeneron), Turning Point Therapeutics (NASDAQ: TPTX, acquired by BMS), Akero Therapeutics (NASDAQ: AKRO), Harmony Biosciences (NASDAQ: HRMY), Pharvaris (NASDAQ: PHVS), CinCor Pharma (NASDAQ: CINC, acquired by Astra Zeneca), RayzeBio (NASDAQ: RYZB, acquired by BMS), and many others. </p>

SAN JOSE -- QuantumScape Corporation, a developer of next-generation solid-state lithium-metal battery technology, has announced…
PALO ALTO – Genspark.ai, the company building an all-in-one AI workspace, has closed a $100 million…
SAN FRANCISCO -- Coval, an evaluation platform for voice AI, has reeled in a $28 million Series…
SAN FRANCISCO -- Sail Research, an infrastructure company for AI agents, has raised $80 million…
Best Buy -- the nation's leading electronics retailer -- is bringing Meta Lab @ Best…
SANTA CLARA — Intel Corporation has appointed Seok-Hee Lee [photo above] as executive vice president…